OR WAIT null SECS
Josh Ludwig detailed to CancerNetwork® how ScaleReady can help make cell and gene therapy widely practical and viable for patients with cancer.
In a recent episode of Deep Dive from the Medical World News® broadcast, CancerNetwork® spoke with Josh Ludwig, the global director of commercial operations at ScaleReady, about how a joint venture launched in January 2021 between Bio-Techne, Fresenius Kabi, and Wilson Wolf is uniquely positioned to make cell and gene therapy practical and viable for patients with cancer.
Ludwig discussed how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also detailed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.